Skip to main content
Margaret Ragni, MD, Hematology, Pittsburgh, PA, UPMC Presbyterian

MargaretVRagniMD

Hematology • Pittsburgh, PA

Professor, Medicine, University of Pittsburgh School of Medicine

Join to view full profile

Dr. Ragni is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Ragni's full profile

Already have an account?

  • Office

    3636 Boulevard of the Allies
    University of Pittsburgh Hemophilia Center of Western PA
    Pittsburgh, PA 15213
    Phone+1 412-209-7288
  • Is this information wrong?

Education & Training

  • University of Pittsburgh Graduate School of Public Health
    University of Pittsburgh Graduate School of Public HealthMPH, Epidemiology, 1991 - 1993
  • UPMC Medical Education
    UPMC Medical EducationFellowship, Hematology and Medical Oncology, 1978 - 1982
  • UPMC Medical Education
    UPMC Medical EducationResidency, Internal Medicine, 1975 - 1978
  • University of Pittsburgh School of Medicine
    University of Pittsburgh School of MedicineClass of 1975

Certifications & Licensure

  • PA State Medical License
    PA State Medical License 1976 - 2024

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • BIVV001 Fusion Protein as Factor VIII Replacement Therapy for Hemophilia A  
    Doris V Quon, Margaret V Ragni, The New England Journal of Medicine

Abstracts/Posters

  • Innate Immune Mechanism of Hemarthrosis in Hemophilia-a Mice
    Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Mechanism of Pulmonary Thrombosis in Hemolytic Disorders
    Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • FVIII Protein Is Not Detectable in Human PBMCs or Livers from Dogs with an Intron-22 Inversion Mutation: Implications for FVIII Immunogenicity and Tolerance
    Margaret V. Ragni, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Join now to see all

Lectures

  • Hemostasis and Thrombosis 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Von Willebrand Disease Minimize Menorrhagia (VWDMin) Trial 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Coagulation Conundrum Roundtable: Case-based Discussion on the Implications of Exogenous Estrogens in Hemostasis and Thrombosis 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Join now to see all

Authored Content

  • Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX VariantDecember 2017

Press Mentions

  • Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young Women
    Coagulation Conundrums: Managing Hemostatic and Thrombotic Complications in Young WomenNovember 8th, 2019
  • Gα13 Is Closely Related to Hematopoiesis in Zebrafish
    Gα13 Is Closely Related to Hematopoiesis in ZebrafishNovember 27th, 2010
  • Gene Therapy Shows Promise in Hemophilia B
    Gene Therapy Shows Promise in Hemophilia BDecember 5th, 2016
  • Join now to see all

Grant Support

  • Training Students In Biomedical Research In HematologyNational Heart, Lung, And Blood Institute2005–2012
  • Hemophilia Adult Prophylaxis StudyNational Heart, Lung, And Blood Institute2011
  • Ph2 Comp Hemostatic Of Escal Doses Interleukin-11 W/Type 1 Von Willebrand DISNational Center For Research Resources2005
  • Impact Of HIV On Hepatitis C In Hemophilia (3HS)National Center For Research Resources2004–2005
  • Ph1 Sfy Sty PTS W/Severe Hemophilia B Using AavvNational Center For Research Resources2004
  • Impact Of HIV On Hepatitis C Infection In HemophiliaNational Heart, Lung, And Blood Institute2001–2004
  • Factor VIII Vector For Severe Hemophilia ANational Center For Research Resources2000–2002
  • Epidemiology And Immunology Of Hemophilia A InhibitorsNational Heart, Lung, And Blood Institute1998–2001
  • Safety/Efficacy Of Kogenate 2 Antihemophilic Factor Recombinant Free Of AlbuminNational Center For Research Resources1998–1999
  • Safety And Efficacy Of Human Recombinant Factor (RHFIX) In Hemophilia B PatientsNational Center For Research Resources1998–1999
  • Safety &Efficacy Of Kogenate-2 Antihemophilic Factor RecombinantNational Center For Research Resources1997
  • Pharmacokinetic, Safety And Efficacy Study Of Human Recombinant Factor (RHFIX)National Center For Research Resources1997
  • Three-Segment, Phase I/II Study Of RH Factor IX In Patients With Hemophilia BNational Center For Research Resources1996
  • Study Of Hiv-Associated Malignancy In HemophiliacsNational Cancer Institute1989–1993
  • Hiv-Associated Malignancy In HemophiliacsNational Cancer Institute1992

Hospital Affiliations

Dr. Margaret Ragni, Dr. Margaret Ragni, MD, Dr. M Ragni, Dr. Margaret V Ragni